7646.T
The company operates in the Food & Drug Retailing sector, generating revenue primarily through the sale of food and drug products to consumers.
Business. The company operates in the Food & Drug Retailing sector, generating revenue primarily through the sale of food and drug products to consumers.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the Food & Drug Retailing sector, generating revenue primarily through the sale of food and drug products to consumers.
The company maintains a relatively balanced capital structure, with a debt-to-equity ratio of 0.4, indicating a moderate reliance on debt financing. However, its liquidity position is assessed as medium, with a current ratio of 1.36, suggesting that the company has sufficient short-term assets to cover its short-term liabilities, but with limited excess. The company's free cash flow is negative at -982 million JPY, which may indicate that capital expenditures are outpacing operating cash flow.
In terms of profitability, the company's return on equity is 8.78%, which is a measure of how effectively the company is using shareholders' equity to generate profits. The return on assets of 3.63% suggests that the company is generating a modest return on its total asset base. These figures should be compared against the industry median to determine if the company is outperforming or underperforming its peers.
The company's revenue is derived from a single business segment, as disclosed in the latest financial data, and there is no indication of geographic diversification provided in the available data. This lack of segment and geographic detail limits the ability to assess the company's exposure to different markets or product lines.
The company's growth trajectory is not explicitly detailed in the provided data, but the negative free cash flow and the capital expenditure of -3.2 billion JPY suggest that the company is investing in its operations. The outlook for the current fiscal year and the next fiscal year is not provided, so it is not possible to determine the expected direction of revenue or profit changes.
The risk assessment indicates that the company faces medium liquidity risk, with a current ratio that is just sufficient to cover short-term obligations. The dilution risk is assessed as low, and there is no indication of dilution potential in the basic shares outstanding. The company's custom valuations do not show any adjustments that would suggest a significant change in valuation due to risk factors.
Recent events, such as filings or transcripts, are not detailed in the provided data, so it is not possible to comment on any recent developments that may have impacted the company's financial position or strategic direction.
- The company has a moderate debt-to-equity ratio, indicating a balanced capital structure.
- The company's liquidity position is medium, with a current ratio that is just sufficient to cover short-term liabilities.
- The company's return on equity is 8.78%, which is a measure of how effectively the company is using shareholders' equity to generate profits.
- The company's free cash flow is negative, suggesting that capital expenditures are outpacing operating cash flow.
- The company's growth trajectory is not explicitly detailed, but the negative free cash flow and capital expenditure suggest investment in operations.
- The company's risk assessment indicates medium liquidity risk and low dilution risk.
- **margin_outlook_rationale**: The company's gross profit margin is 22.83%, which is a key indicator of its ability to maintain profitability in the face of cost pressures.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 7646.T Market data — financials · 2026-05-27